| Similar Articles |
|---|
 |
The Motley Fool
June 15, 2010
Ryan McBride |
Genzyme Borrows $1 Billion for Stock Buyback Notes will be sold this week.   |
The Motley Fool
September 23, 2010
Ryan McBride |
Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault. |
The Motley Fool
May 14, 2010
Ryan McBride |
Genzyme in "Tough Spot" With Icahn Proxy Challenge Carl Icahn is pushing for change, but Genzyme's CEO has been pushing back. |
The Motley Fool
June 10, 2010
Brian Orelli |
Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday. |
The Motley Fool
October 4, 2010
Ryan McBride |
Sanofi-Aventis Launches Hostile Takeover Bid for Genzyme The French drug giant makes a tender offer of $69 a share. |
The Motley Fool
February 23, 2010
Brian Orelli |
Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year. |
The Motley Fool
September 11, 2010
Luke Timmerman |
Genzyme Cutting 1,000 Jobs Over Next 15 Months The biotech powerhouse has had a tough stretch of late, and now it says it must lay off some of its workforce. |
The Motley Fool
May 26, 2010
Brian Orelli |
Is This 4,000-Liter Bioreactor Half-Full? Or half-empty? Only time will tell for Genzyme. |
The Motley Fool
April 8, 2010
Brian Orelli |
Is Icahn Stuck in the Station? Saving Genzyme's train wreck may be difficult. |
The Motley Fool
October 4, 2006
Brian Lawler |
Unwelcome Guests at ImClone ImClone's board of directors votes against Carl Icahn's proposed removal of six company directors. Short-term shareholders that are able to cash out with Icahn, will possibly have a nice gain to take home. |
The Motley Fool
September 6, 2006
Brian Lawler |
AnorMED's Tumultuous Year A takeover attempt follows management shakeups at the biopharmaceutical firm. Investors, take note. |
The Motley Fool
August 30, 2010
Ryan McBride |
Genzyme Shoots Down Sanofi-Aventis's Buyout Offer Genzyme would be a prize for several major drug companies in need of new revenue streams. |
The Motley Fool
March 23, 2010
Brian Orelli |
Icahn and Biogen Kiss and Make Up He gets one more seat on the board, so what's next? |
The Motley Fool
July 26, 2010
Brian Orelli |
Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete? |
The Motley Fool
May 29, 2008
Brian Lawler |
Icahn Girds for Biogen Battle The activist investor officially launches his bid to usurp Biogen's board of directors. |
The Motley Fool
October 22, 2009
Brian Orelli |
The Gift That Keeps on Giving Genzyme's manufacturing issues just won't go away. Four months after the company announced that it had shut down a manufacturing plant because of viral contamination, its stock is still dealing with the aftermath. |
The Motley Fool
January 29, 2008
Brian Lawler |
Icahn Tries to Board USS Biogen Carl Icahn and the funds that he runs announce that they will try to get elected to three seats on the board of directors at Biogen Idec. |
The Motley Fool
February 17, 2010
Brian Orelli |
Execute Well or You're Out Genzyme needs to show investors that it can rebuild. |
Chemistry World
October 5, 2010
Andrew Turley |
Sanofi hostile move for Genzyme Sanofi-Aventis has taken its $69-per-share ( 44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board. |
The Motley Fool
January 29, 2010
Brian Orelli |
Icahn Back to Batter Biogen The old guy has tenacity. |
The Motley Fool
November 24, 2010
Brian Orelli |
Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant. |
The Motley Fool
November 12, 2010
Alyce Lomax |
Welcome to Proxy Fight Club Despite their downsides, proxy wars represent an important part of shareholder rights. |
The Motley Fool
August 20, 2010
Brian Orelli |
This Billionaire Likes Biotech. Should You? It depends on how much you trust management. |
The Motley Fool
November 19, 2009
Brian Orelli |
This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous. |
The Motley Fool
June 11, 2008
Brian Lawler |
He Said, Biogen Said Pharmaceutical Biogen Idec's battle with Carl Icahn is coming to a head. |
The Motley Fool
January 5, 2010
Brian Orelli |
A Deal Manufactured by Necessity Genzyme gets some help from a new friend. |
The Motley Fool
January 30, 2009
Brian Orelli |
Icahn's Next Target Activist investor Carl Icahn has decided to nominate a slate of five directors for the board of Amylin Pharmaceuticals, of which he owns 8.3%. |
The Motley Fool
January 18, 2012
Dawn Kawamoto |
Yahoo!'s Yang Out, Board Selection Trumps New CEO Selection Yahoo! is reportedly on the prowl for new board directors, as shareholder activist Third Point LLC is increasing pressure to name its own competing slate. |
The Motley Fool
January 9, 2008
Brian Lawler |
Tracking Genzyme The biopharma updates investors on what to expect for 2008. |
The Motley Fool
April 30, 2007
Tom Taulli |
Proxy Fights 101 How shareholder skirmishes are transforming Wall Street. It's smart to understand how proxy fights work, but don't assume they're a good system for investing. Proxy battles often target struggling companies with volatile stocks. |
The Motley Fool
April 15, 2005
Tom Taulli |
Carl Icahn Strikes Again Energy and inorganic-chemical company Kerr-McGee and investor Icahn make peace. The market's happy, and Icahn's war chest just gets bigger. |
Chemistry World
February 17, 2011
Sarah Houlton |
Sanofi to buy Genzyme in $20 billion deal Sanofi-Aventis has won its long-running battle for Genzyme, and is to acquire the US-based biotech for $74 ( 46) per share - about $20 billion in total - plus extra payments of up to $14 per share. |
The Motley Fool
July 26, 2006
Rich Duprey |
infoUSA's Undependable Independence The embattled database firm appoints a top independent director who's anything but. Investors, take note. |
The Motley Fool
June 4, 2009
Brian Orelli |
Ignore Icahn's Hoopla Carl Icahn and his fights with management at Biogen's Idec make for entertaining news coverage, but investors shouldn't spend too much time analyzing how the antics are going to affect the share price. |
The Motley Fool
July 26, 2010
Ryan McBride |
How Much Would You Pay for Genzyme? Speculation has erupted over the potential outcome of reported M&A talks between the Cambridge, MA-based biotech powerhouse Genzyme and the French drug giant Sanofi-Aventis |
The Motley Fool
August 3, 2010
Brian Orelli |
Drama Continues: What's Genzyme Worth to Sanofi? Just get on with it, Sanofi and Genzyme. How much is Genzyme worth? Whatever its board of directors is willing to let it go for. |
The Motley Fool
June 22, 2011 |
Here's What Carl Icahn Bought and Sold Last Quarter A look under the hood at what Carl Icahn was up to in the first three months of 2011. |
BusinessWeek
March 5, 2007
Ronald Grover |
Just Don't Call Him A Raider Carl Icahn, who now styles himself a shareholder activist, prepares for battle with Motorola. |
The Motley Fool
October 27, 2010
Selena Maranjian |
When Hostile Takeovers Get Ugly Conflict between companies and potential buyers can spill over to hurt shareholders. |
The Motley Fool
March 3, 2011
Ryan McBride |
With Sanofi Buyout of Genzyme, Rare Disease Execs Upbeat About Interest in Their Niche The field might benefit from the increased interest in it among pharmaceutical players. |
The Motley Fool
October 10, 2007
Brian Lawler |
Bioenvision Demands a Recount Bioenvision decided to hold the polls open one more day, in hopes that some stockholders who hadn't yet participated would vote for their proposed acquisition by Genzyme. |
The Motley Fool
September 13, 2010
Brian Orelli |
When All Else Fails, Sell! Genzyme has no other choice. |
The Motley Fool
July 12, 2006
Brian Lawler |
Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share. |
Pharmaceutical Executive
March 1, 2006
Sara Calabro |
Genzyme: The Price of Success Genzyme put patients first, and grew to become a multi-billion-dollar company. But empires don't survive on altruism. |
The Motley Fool
September 15, 2011
Dawn Kawamoto |
Reshuffling Yahoo!'s Board: A New House of Cards? It may take an activist shareholder to bring about meaningful change. |
InternetNews
March 26, 2008 |
Motorola to Split Into Two Motorola said on Wednesday it would split into two publicly traded entities to separate its loss-making handset division from its other businesses. |
The Motley Fool
June 21, 2010
Erin Kutz |
Curis Misses Mark in Drug Trial; Genzyme Elects Board; GTC Cuts Jobs; and More Boston-Area Life Sciences News These drug and biomedical companies made news last week. |
The Motley Fool
May 28, 2009
Brian Orelli |
Best of Both Worlds Fresh blood on Amylin's Board of Directors should be able to offer a new opinion as to how things should change without disrupting the company's progress. |
The Motley Fool
July 8, 2008
Rick Aristotle Munarriz |
Doesn't Yahoo! Get a Say? Billionaire investor Carl Icahn and Microsoft insist that only a new boardroom -- ideally populated by the slate of directors that Icahn is proposing -- will lead Microsoft to reopen acquisition talks with Yahoo!. |
The Motley Fool
October 25, 2006
Brian Lawler |
Earnings Soothe ImClone Investors For long-term shareholders of ImClone stock, it will be hard to bask in the glory of ImClone's positive earnings for long. Numerous looming issues surround the company, including the Yeda patent dispute, coming competition from Amgen's Vectibix, and possible shareholder shenanigans from Icahn. |
